)
Visual
earnings real time
GlucoTrack (GCTK) investor relations material
GlucoTrack Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary13 Nov, 2025
Executive summary
Developing a fully implantable continuous blood glucose monitor (CBGM) with a 3-year sensor life, targeting diabetes patients requiring daily monitoring.
Completed a first-in-human clinical study outside the US, meeting all endpoints with no serious adverse events and high accuracy (MARD 7.7%).
Advanced clinical and corporate objectives, including progress toward FDA IDE submission for CBGM technology in Spring 2026.
Initiated a long-term, multicenter feasibility study in Australia for the CBGM product, with protocol amendments underway to refine participant selection.
Presented at major diabetes conferences, highlighting strong endocrinologist interest in the implantable CBGM and integrated device management for chronic conditions.
Financial highlights
Net loss for the nine months ended September 30, 2025, was $15.8 million, up from $12.5 million year-over-year.
Net loss for the quarter was $4.2 million, down from $5.1 million in the prior-year quarter.
Cash and cash equivalents at September 30, 2025, were $7.9 million, up from $5.6 million at year-end 2024.
Operating expenses for the nine months were $12.6 million, up from $10.7 million year-over-year, driven by increased R&D and G&A costs.
Research and development expenses rose to $3.2 million for Q3 2025 (from $2.1 million in Q3 2024) and $8.2 million for the nine months (from $7.8 million in 2024).
Outlook and guidance
IDE submission to the FDA for the CBGM product is planned for Spring 2026, aiming to initiate a U.S. long-term, multicenter pilot study.
Current cash is insufficient to fund operations for the next 12 months; approximately $15 million in additional funding is needed.
Cash position expected to fund operations through March 2026, including clinical trials and milestone achievements.
Plans to raise further capital through equity, debt, or other arrangements; failure to secure funding may delay or halt operations.
Plans to present additional clinical data and further expand advisory boards with leading experts.
Australia study issues impact on US IDE timeline?
Explain significant share count increase
Epidural glucose monitoring market strategy
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next GlucoTrack earnings date
Q4 202531 Mar, 2026
Next GlucoTrack earnings date
Q4 202531 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
GlucoTrack, Inc. is a medical device company focused on developing and commercializing innovative technologies designed for people with diabetes. The company’s flagship product, also named GlucoTrack, is a non-invasive glucose monitoring device that allows users to obtain blood glucose readings without the need for fingersticks or other invasive procedures. Additionally, GlucoTrack is working on a long-term implantable continuous blood glucose monitor (CBGM) aimed at providing accurate, continuous glucose monitoring for extended periods, addressing challenges such as calibration and comfort found in traditional CGM systems. GlucoTrack, Inc. is headquartered in Rutherford, New Jersey, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage